Early detection of prostate cancer: Serendipity strikes again

JAMA

Volumn 278, Issue 18, 1997, Pages 1516-1519

  Collins, Mary McNaughton ^a   Ransohoff, David F ^b   Barry, Michael J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 1842292722     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.1997.03550180066039     Document Type: Article

References (34)

1. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? I: framing the debate. Urology. 1995;46:2-13.
2. Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med. 1995;333:1401-1405.
3. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening. Ann Intern Med. 1993;119:914-923.
4. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. JAMA. 1994;272:773-780.
5. US Preventive Services Task Force. Screening for prostate cancer. In: Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:119-134.
6. Ransohoff DF, Lang CA. Small adenomas detected during fecal occult blood test screening for colorectal cancer. JAMA. 1990;264:76-78.
7. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365-1371.
8. Richie JP, Catalona WJ, Ahmann FR, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal exam. Urology. 1993;42:365-374.
9. Gann PH, Hennekens CH, Stampfer MF. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995; 273:289-294.
10. Barry MJ. PSA level had moderate sensitivity for prostate cancer presenting within 4 years (commentary). ACP Journal Club. 1995;123:19.
11. Karakiewicz PI, Aprikian AG, Meshref AW, Bazinet M. Computer-assisted comparative analysis of four-sector and six-sector biopsies of the prostate. Urology. 1996;48:747-750.
12. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol. 1997;157:199-203.
13. Levine MA, Melamed J, Ittmann M, Lepor H. Two consecutive sets of transrectal ultrasound (TRUS) guided sextant biopsies of the prostate for the diagnosis of prostate cancer. J Urol. 1997;157 (suppl):64. Abstract.
14. Harmon T, Keetch DW, Catalona WJ. Diagnostic value of serial prostate biopsies in men with normal prostate-specific antigen (PSA) levels and suspicious digital rectal examination (DRE). J Urol. 1997;157(suppl):365. Abstract.
15. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. Patient age and prostate gland size determine the appropriate number of cores per prostate biopsy. J Urol. 1997;157(suppl):365. Abstract.
16. Billebaud T, Villers A, Astier L, et al. Advantage of systematic random ultrasound-guided biopsies, measurement of serum prostate-specific antigen level and determination of prostate volume in the early diagnosis of prostate cancer. Eur Urol. 1992;21:6-14.
17. Flanigan RC, Catalona WJ, Richie JP, et al. Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol. 1994;152:1506-1509.
18. Brawn PN, Speights VO, Kuhl D, et al. Prostate-specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer. 1991;68: 1592-1599.
19. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients. J Urol 1989;141:1076-1083.
20. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916.
21. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Urol Clin North Am. 1993;20:687-693.
22. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate-specific antigen based screening. J Urol. 1996;155:816-820.
23. Scaletscky R, Koch MO, Eckstein CW, Bicknell SL, Gray GF, Smith JA. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate-specific antigen. J Urol. 1994;152:129-131.
24. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
25. Ohori M, Wheeler TM, Scardino PT. The new American Joint Committee on Cancer and International Union Against Cancer TNM Classification of prostate cancer. Cancer. 1994;74:104-114.
26. Mettlin C, Jones G, Averett H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup. CA Cancer J Clin. 1993;43:42-47.
27. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol. 1992;23:211-222.
28. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer. J Urol. 1994;151:1283-1290.
29. Coley CM, Barry MJ. Fleming C, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? II: early detection strategies. Urology. 1995;42:125-141.
30. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 1996;275:288-294.
31. Geary ES, Stamey TA. Pathological characteristics and prognosis of nonpalpable and palpable prostate cancers with a Hybritech prostate-specific antigen of 4 to 10 ng/ml. J Urol. 1996;156:1056-1058.
32. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal, and ovarian screening trial of the National Cancer Institute. J Urol. 1994;152:1905-1909.
33. Prorok P. The National Cancer Institute multi-screening trial. Can J Oncol. 1994;4(suppl):98-101.
34. Schröder FH. The European Screening Study for Prostate Cancer. Can J Oncol. 1994;4(suppl):102-105.